Human Gene Therapy Clinical Development

Human Gene Therapy is the premier, multidisciplinary journal covering all aspects of gene therapy. The Journal publishes in-depth coverage of DNA, RNA, and cell therapies by delivering the latest breakthroughs in research and technologies. Human Gene Therapy provides a central forum for scientific and clinical information, including ethical, legal, regulatory, social, and commercial issues, which enables the advancement and progress of therapeutic procedures leading to improved patient outcomes, and ultimately, to curing diseases.The Journal is divided into three parts. Human Gene Therapy, the flagship, is published 12 times per year. HGT Methods, a bimonthly journal, focuses on the applications of gene therapy to product testing and development. HGT Clinical Development, a quarterly journal, serves as a venue for publishing data relevant to the regulatory review and commercial development of cell and gene therapy products.Complete coverage includes: Improvements in vector developments Delivery systems Cell therapy Small nucleic acid therapeutics, including RNAi Clinical trials and animal models Clinical protocols Pre-clinical animal and in vitro studies to assess the safety of gene and cell therapy products used to support clinical applications Clinical trials including those in which the results are confirmatory or negative Topical issues related to the commercial development of gene and cell therapy productsHuman Gene Therapy was voted one of the most influential journals in Biology and Medicine over the last 100 years by the Biomedical & Life Sciences Division of the Special Libraries Association.Human Gene Therapy, HGT Methods, and HGT Clinical Development are under the editorial leadership of Editor-in-Chief Terence R. Flotte, MD, University of Massachusetts Medical School; Deput Editors Europe Nathalie Cartier, MD, INSERM, and Thierry VandenDriessche, PhD, Free University of Brussels (VUB); Deputy Editors U.S. Barry J. Byrne, MD, PhD, Powell Gene Therapy Center, University of Florida, College of Medicine and Mark A. Kay, MD, PhD, Stanford University School of Medicine; Human Gene Therapy Editor Guangping Gao, PhD, University of Massachusetts Medical School; Methods Editor Hildegard Büning, PhD, Hannover Medical School; Clinical Development Editor James M. Wilson, MD, PhD, University of Pennsylvania School of Medicine, Gene Therapy Program; and other leading investigators. View the entire editorial board.Audience: Geneticists, medical geneticists, molecular biologists, virologists, experimental researchers, and experimental medicine specialists, among others.Human Gene Therapy and HGT Methods provide “Instant Online” publication 72 hours after acceptance

Human Gene Therapy Clinical Development期刊中文简介

《人类基因治疗》是一本涵盖基因治疗各个方面的多学科杂志。该杂志通过提供最新的研究和技术突破，对DNA、RNA和细胞疗法进行了深入报道。人类基因治疗为科学和临床信息提供了一个中心论坛，包括伦理、法律、监管、社会和商业问题，使治疗程序的进步和进步能够改善患者的结果，并最终治愈疾病。该期刊分为三个部分。人类基因疗法是其旗舰，每年出版12期。《HGT Methods》是一本双月刊，主要研究基因治疗在产品检测和开发中的应用。HGT临床发展是一份季刊，作为发布与细胞和基因治疗产品的监管审查和商业开发相关的数据的场所。完整的覆盖范围包括:向量发展的改善运载系统细胞疗法小型核酸疗法，包括RNAi临床试验和动物模型临床协议临床前动物和体外研究评估用于支持临床应用的基因和细胞治疗产品的安全性临床试验，包括结果证实性或阴性的临床试验与基因和细胞治疗产品的商业开发相关的热点问题《人类基因疗法》被美国特殊图书馆协会生物医学与生命科学部评选为近100年来生物学和医学领域最具影响力的期刊之一。人类基因治疗、HGT方法和HGT临床开发由麻省大学医学院医学博士特伦斯·r·弗洛特主编;Deput欧洲编辑Nathalie Cartier，医学博士，INSERM，和Thierry VandenDriessche，博士，布鲁塞尔自由大学(VUB);美国佛罗里达大学医学院鲍威尔基因治疗中心副编辑Barry J. Byrne医学博士，斯坦福大学医学院Mark A. Kay医学博士;人类基因治疗编辑高广平，麻省大学医学院博士;方法编辑Hildegard Buning，博士，汉诺威医学院;临床发展编辑James M. Wilson，医学博士，宾夕法尼亚大学医学院，基因治疗项目;以及其他主要调查人员。查看整个编辑委员会。观众:遗传学家、医学遗传学家、分子生物学家、病毒学家、实验研究人员、实验医学专家等。人类基因治疗和HGT方法提供“即时在线”出版后72小时接受